Drug discovery and repurposing of drugs

This research area aims at setting up capabilities for drug discovery and repurposing of existing drugs for COVID-19, and starting pilot projects towards identification of lead molecules (chemicals and biomolecules). Additional aim is to coordinate technologies, capabilities and national expertise, such as data-driven (chemoinformatic) approaches. 

This area consists of 10 individual projects, funded a total of 8,7 MSEK. Led by researchers at Uppsala University, KTH Royal Institute of Technology, Karolinska Institutet and University of Gothenburg.

The Drug Repurposing set from SPECS is now available through Compound Center.

Coordinator: Jeannette Dypbukt, Karolinska Institutet

Scientific lead: Kristian SandbergUppsala University, and Anna-Lena GustavssonKarolinska Institutet


NEVERMORE COVID – Establishing a drug discovery platform for corona virus disease
Kristian Sandberg, Uppsala University

A high-quality drug repurposing set
Anna-Lena Gustavsson, Karolinska Institutet

Multi-level profiling of Coronavirus-infected cells by combining Viral Entry Assays, Cell Painting, and DrugSEQ
Ola Spjuth, Uppsala University

Spatial single cell mapping of SARS-CoV-2 interacting host proteins for quick and targeted drug repurposing
Charlotte Stadler, KTH

FragCor – Fragment based NMR screen targeting SARS-Cov-2 proteins
Göran Karlsson, University of Gothenburg 

An adaptable therapeutic technology platform to treat SARS-CoV infections in immune suppressed individuals
Sara Mangsbo, Uppsala University

Rapid testing for treatment of Covid-19
Kristina Nyström, Sahlgrenska University Hospital

Discovery of SARS-CoV-2 Inhibitors by Virtual Screening of Ultra-large Chemical Space
Jens Carlsson, Uppsala University

Chemographic characterization of compounds binding to seven identified molecular targets from SARS-CoV-2
Anders Backlund, Uppsala University    

Distributed computing to generate the druggable conformational ensemble of sars-cov-2 proteins
Lucie Delemotte, KTH

Read more

Last updated: 2024-02-23

Content Responsible: Alice Sollazzo(alice.sollazzo@scilifelab.uu.se)